Bausch Health Companies Inc (NYSE/TSX: BHC), a Canada-based multinational specialty pharmaceutical company, announced on Wednesday that it has received an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4mg/ml, from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland.
The product is intended to treat COVID-19 in adult and adolescent patients over 12 years of age and older, weighing around 40kg and in need of oxygen therapy. It is a corticosteroid that decreases inflammation.
The United States Food and Drug Administration (FDA) has not granted approval to Dexamethasone-containing products in the United States for the treatment for COVID-19. The products are only to be used in accordance with their approved label and under the directions of the patient's doctor.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins